Cipla Limited has informed the Exchange regarding Outcome of Board Meeting held on May 13, 2026.

Cipla's board of directors approved four key items at their meeting on May 13, 2026. First, the 90th Annual General Meeting is scheduled for June 25, 2026. Second, the company granted stock options under ESOS 2013-A (totaling 176,389 options at INR 2 exercise price) and Employee Stock Appreciation Rights under ESAR 2021 (totaling 596,244 ESARs at INR 2 per share) to employees. Third, M/s Joshi Apte & Associates was appointed as Cost Auditors for FY 2026-27. Fourth, Mr Sushrut Kulkarni was appointed as President & Global Chief – Integrated Product Development, effective May 18, 2026, bringing over three decades of pharmaceutical R&D experience from Dr Reddy's, Glenmark, and Zydus.